Last edition
News about "TG4050"
Transgene, NEC Bio B.V. Sign Licensing Deal to Advance AI-Driven Cancer Vaccine
Transgene's Agreement wirh NEC Bio B.V. to accelerate development of TG4050, a personalised neoantigen immunotherapy for head and neck cancer, combining viral vector technology with AI-based prediction.
TG4050 | 07/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members